A Randomized, Double-blind, Placebo-controlled Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.1 个研究点分布在 1 个国家目标入组 90 人开始时间: 2026年3月31日最近更新: 2026年5月8日

适应症

干预措施

试验速览

阶段: 1 期
状态: 招募中
发起方: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
入组人数: 90
试验地点: 1
主要终点: Number of participants with adverse events (AEs) /TEAEs

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This is a randomized, double-blind, placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of SKB575. This study consists of two parts. Phase Ia is a single ascending dose study in healthy subjects and Phase Ib is a proof-of-concept study in patients with moderate to severe atopic dermatitis.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围: 18 Years 至 70 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 是

入选标准

•Phase Ia healthy participants must meet all of the following inclusion criteria to be enrolled:
•The participant is able to understand and comply with the requirements of the study and voluntarily signs the informed consent form.
•Age at the time of signing the informed consent form is 18-55 years (inclusive), any gender.
•Male participants weigh ≥ 50.0 kg, female participants weigh ≥ 45.0 kg; body mass index [BMI] is 18.0-28.0 kg/m² (inclusive).
•No clinically significant abnormalities.
•Phase Ib participants with moderate to severe AD must meet all of the following inclusion criteria to be enrolled:
•The participant is able to understand and comply with the requirements of the study and voluntarily signs the informed consent form.
•Age at the time of signing the informed consent form is 18-70 years (inclusive), any gender.
•Participant weight must be ≥ 45.0 kg.
•At screening, the diagnosis of AD meets the American Dermatology Consensus Criteria (2014) (see Appendix 4) and disease duration is ≥ 1 year; and at both screening and randomization, all of the following conditions are satisfied:
•EASI ≥ 16 at screening and baseline visits;
•IGA ≥ 3 (on a 0 4 IGA scale, where 3 = moderate, 4 = severe) at screening and baseline visits;
•Body surface area (BSA) of lesions ≥ 10% at screening and baseline visits.
•Prior to screening, the participant has received at least 4 weeks of potent or 2 weeks of super potent topical corticosteroids (or systemic corticosteroids), or topical calcineurin inhibitor.

排除标准

•History of any clinically significant disease of the cardiovascular, hematological, hepatic, renal, digestive, neurological, respiratory, or psychiatric systems, or metabolic disorders, or any other disease or physiological condition that may interfere with the trial results.
•History of malignancy, regardless of whether treated, and regardless of the presence or absence of signs of local recurrence or metastasis.
•Presence of skin scars, induration, inflammation, edema, ulceration, infection, bleeding, or other conditions at the intended injection site that are unsuitable for subcutaneous injection.
•Clinical signs of active infection within 4 weeks prior to randomization, including but not limited to urogenital infection, pulmonary infection, acute sinusitis, appendicitis, bloodstream infection, etc.
•History of tuberculosis or complications of tuberculosis, or positive/abnormal findings of clinical significance based on chest X-ray/chest CT, physical examination, and T-cell interferon-gamma release assay (TIGRA) (e.g., T-Spot or Quanti-FERON®-TB Gold™).
•Subjects positive for Hepatitis B (HBsAg, HBeAg, HBeAb, or HBcAb), positive for Hepatitis C antibody, positive for HIV antibody, or positive for syphilis serology.
•NOTE: The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.